Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    blinart
Previous Study | Return to List | Next Study

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03931642
Recruitment Status : Active, not recruiting
First Posted : April 30, 2019
Last Update Posted : February 8, 2022
Information provided by (Responsible Party):
French Innovative Leukemia Organisation

Brief Summary:

Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE®) antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation and subsequent lysis of tumor cells.

The investigators propose to evaluate the efficacy, safety and tolerability of blinatumomab administered after R-CHOP debulking therapy in patients with Richter Syndrome (RS) of diffuse large B-cell lymphoma (DLBCL) histology.

The investigators hypothesize that 8-week blinatumomab induction therapy leads to Complete Response (CR) rate improvement (revised Cheson criteria) from a baseline of 7percent as observed in the prospective study evaluating R-CHOP.

Condition or disease Intervention/treatment Phase
Richter Syndrome Drug: RCHOP Drug: Blinatumomab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation
Actual Study Start Date : July 5, 2019
Actual Primary Completion Date : October 1, 2021
Estimated Study Completion Date : July 4, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: R-CHOP- blinatumomab

Patients will first undergo a prior debulking therapy including 2 cycles of R-CHOP.

At Day1 (D1) : Rituximab 375 mg/m² Intravenous (IV) + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.

From D1 to D5 : Prednisone 60 mg/m² Per Os (PO). Patients with CR and no measurable lesion left will not be treated further in the setting of the present trial. All the remaining patients will be continuing and treating on study with a single cycle of blinatumomab induction therapy : Blinatumomab at 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/d from day 15-56.

Patients who achieve an objective response after induction are eligible to receive one further optional cycle of blinatumomab consolidation : blinatumomab 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/day IV from day 15-28.


D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.

From D1 to D5 : Prednisone 60 mg/m² PO.

Drug: Blinatumomab
Blinatumomab by continuous vein infusion

Primary Outcome Measures :
  1. Complete remission (CR) rate according to the revised Lugano criteria [ Time Frame: at week 16 from baseline ]
    the objective response rate to one 8-week cycle of blinatumomab following a debulking therapy with 2 R-CHOP cycles

Secondary Outcome Measures :
  1. Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: From the first treatment administration and during treatment period (R-CHOP and blinatomomab) ]
    safety and toxicity of blinatumomab after 2 cycles of R-CHOP

  2. overall response [ Time Frame: At week 16 from baseline, after blinatumomab induction and at week 24 after blinatumomab consolidation. ]
    Overall response rate (revised Lugano criteria) after the first and second cycle of blinatumomab,

  3. CR rate [ Time Frame: After blinatumomab consolidation (total of 4 weeks) at week 24 from the beginning of study treatment. ]
    CR rate (revised Lugano criteria) after the second cycle of blinatumomab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma according to the revised iwCLL criteria19 with biopsy proven transformation to diffuse large B-cell lymphoma, consistent with RS according to the 2016 WHO classification
  • Both patients with previously treated or treatment-naïve CLL are eligible
  • Age greater than or equal to 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status <3
  • Patients must meet the following hematologic criteria at screening, unless they have significant bone marrow involvement of either CLL or RS cells confirmed on biopsy: absolute neutrophil count ≥1.0 G/L, platelet count ≥50 G/L independent of transfusion within 7 days of screening
  • Subject must have adequate coagulation, renal, and hepatic function at screening
  • Adequate left ventricular ejection function (> 50 %)
  • Patients who have undergone prior allogeneic hematopoietic stem-cell transplantation (HSCT) are eligible as long as they do not have significant active graft versus host disease and that their transplant day 0 is > 6 months from their first dose of protocol therapy
  • Female patients of child bearing potential must have negative pregnancy test and use an effective method of birth control during treatment period and 48h thereafter; Males must use an effective method of birth control during treatment period and 48h thereafter.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients with the Hodgkin variant of RS
  • Patients with previously treated RS
  • History or presence of clinically relevant disorder affecting the central nervous system (CNS)
  • Known active DLBCL in the CNS (confirmed by cerebrospinal fluid analysis)
  • Steroids treatment (≥ 20 mg for one week) before inclusion
  • HSCT within 6 months before inclusion
  • Active graft-versus-host disease
  • History of other malignancies, except: i) malignancy treated with curative intent and with no recurrence over the last 5 years ii) adequately treated non-melanoma skin cancer without evidence of disease iii) adequately treated carcinoma in situ without evidence of disease
  • History of human immunodeficiency virus
  • Hepatitis B or C seropositivity (unless clearly due to vaccination)
  • Pregnant or breastfeeding women
  • Unwilling or unable to participate in all required study evaluations and procedures.
  • Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form and authorization to use protected health information (in accordance with national and local subject privacy regulations)
  • Abnormal screening laboratory values as defined as following: a) serum glutamate oxaloacetate transaminase and/or serum glutamate pyruvate transaminase and/or alkaline phosphatase > or =5 x upper limit of normal (ULN); b) Total bilirubin > or = 1.5 x ULN, unless due to Gilbert's disease; c) Creatinine > or = 2.0 x ULN or creatinine clearance <50 mL/min (calculated).
  • Fertile male and female patients who cannot or do not wish to use an effective method of contraception during treatment and for 48h after the final treatment used for the purposes of the study
  • Treatment with other investigational agent or participating to another trial within 30 days prior to entering the study
  • No affiliated to social security

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03931642

Show Show 28 study locations
Sponsors and Collaborators
French Innovative Leukemia Organisation
Layout table for investigator information
Principal Investigator: Romain GUIEZE University Hospital, Clermont-Ferrand
Layout table for additonal information
Responsible Party: French Innovative Leukemia Organisation Identifier: NCT03931642    
Other Study ID Numbers: FILOCLL13-BLINART
First Posted: April 30, 2019    Key Record Dates
Last Update Posted: February 8, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents